GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sutro Biopharma Inc (FRA:S09) » Definitions » Stock Based Compensation

Sutro Biopharma (FRA:S09) Stock Based Compensation : €22.6 Mil (TTM As of Jun. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Sutro Biopharma Stock Based Compensation?

Sutro Biopharma's Stock Based Compensation for the three months ended in Jun. 2024 was €5.7 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 was €22.6 Mil.


Sutro Biopharma Stock Based Compensation Historical Data

The historical data trend for Sutro Biopharma's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sutro Biopharma Stock Based Compensation Chart

Sutro Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial 9.28 9.80 20.57 24.83 22.84

Sutro Biopharma Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.15 5.62 5.70 5.58 5.72

Sutro Biopharma Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €22.6 Mil.


Sutro Biopharma Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Sutro Biopharma's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Sutro Biopharma Business Description

Traded in Other Exchanges
Address
111 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Sutro Biopharma Inc is clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.

Sutro Biopharma Headlines

No Headlines